[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"benign-prostate-hyperplasia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:benign-prostate-hyperplasia":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,56,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100614737","early-versus-delayed-trial-without-catheter-in-men-with-acute-urinary-retention-100614737",false,"NCT07283484","Early Versus Delayed Trial Without Catheter in Men With Acute Urinary Retention.","Early Versus Delayed Trial Without Catheter in Men With Acute Urinary Retention: a Randomized Controlled Trial (the RELIEF Study).","RELIEF","Inclusion Criteria:\n\n* Adult men (≥18 years)\n* Diagnosis of acute urinary retention (AUR) treated with a transurethral catheter (TUC) and alpha-blocker therapy (tamsulosin, silodosin, or alfuzosin)\n* Mentally competent and able to understand the potential benefits and burdens of study participation\n* Provision of written or digital informed consent\n\nExclusion Criteria:\n\n* Failed prior TWOC within the preceding 30 days\n* Initial urinary retention volume \\>1500 mL\n* Neurogenic bladder dysfunction (e.g., multiple sclerosis, spinal cord injury, spina bifida)\n* History of prostate cancer with ISUP grade group ≥2\n* History of active bladder cancer or ongoing surveillance for bladder cancer\n* Urinary retention occurring within 72 hours after surgery (postoperative urinary retention)\n* History of lower urinary tract surgery (e.g., bladder augmentation, urethral surgery, or prostate surgery)\n* AUR suspected to be caused by bladder stones\n* Suspected urethral stricture, clot retention, or urosepsis\n* Contraindication to alpha-blocker therapy","MALE","18 Years",{"count":20,"type":21},478,"ESTIMATED","INTERVENTIONAL",[24],"NA","Acute urinary retention (AUR) is a sudden and painful condition. It occurs when a person is unable to urinate. In men, AUR is most often caused by an enlarged prostate, known as benign prostatic hyperplasia (BPH), which blocks the urethra. The first steps in treatment are to insert a catheter to empty the bladder and to start medication that acts on the prostate (an alpha-blocker). After some time, the catheter is removed during a so-called \"Trial Without Catheter\" (TWOC) to see whether the patient can urinate normally again.\n\nAt present, it is unclear how long a catheter should remain in place before this trial is performed. In Dutch hospitals, the duration varies widely: in some hospitals, the catheter is removed after only a few days, while in others it stays in place for two weeks or longer. A longer catheter duration can cause more discomfort and complications, such as urinary tract infections or blood in the urine. Therefore, it is important to determine whether a shorter catheterization period is equally effective and safe compared to a longer one.\n\nThe RELIEF study investigates whether a short catheter duration of three days is as safe and effective as the current average of fourteen days. A total of 478 men with acute urinary retention will participate in this nationwide randomized controlled trial. All participants will receive a catheter and start (or continue) treatment with an alpha-blocker. They will then be randomly assigned to one of two groups: one group will have the catheter removed after three days, and the other group after fourteen days.\n\nThe main question is whether a shorter catheter duration is as successful as a longer one. Success means that the patient can urinate normally after catheter removal, without needing to have the catheter replaced. The study will also compare the number of complications, patients' experiences with the catheter, their quality of life, and the overall healthcare costs.\n\nBy conducting this study, doctors will gain better evidence on the optimal timing of catheter removal in men with AUR. The goal is to avoid unnecessarily long catheterization, reduce discomfort and complications, and improve the quality of care for men with AUR. The results of the RELIEF study may help improve the management of AUR, making care more consistent, efficient, and patient-friendly both in the Netherlands and abroad.",[27,28,29,30],"Acute Urinary Retention","Benign Prostate Obstruction","Benign Prostate Hyperplasia","Benign Prostate Hypertrophy(BPH)",[15,27,32,33,34,35,36,37,38,39,40,41,42],"Urinary Retention","TWOC","Trial Without Catheter","bladder catheter","urinary catheter","catheter removal","catheter withdrawal","Benign prostate obstruction","BPO","Benign prostate hyperplasia","BPH","RECRUITING","2025-12-15",{"date":46,"type":47},"2025-12-22","ACTUAL",{"date":49,"type":47},"2025-08-21",{"date":51,"type":21},"2029-03-01",{"name":53,"class":54},"Liselot Ribbert","OTHER",11,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":22,"phases":66,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100598416","effect-of-text-message-reminders-on-m-isi-score-after-prostate-surgery-100598416","NCT07071207","Effect of Text Message Reminders on M-ISI Score After Prostate Surgery","Effect of Text Message Reminders on Michigan Incontinence Symptom Index Score After Prostate Surgery","TextMsgM-ISI","Inclusion Criteria:\n\n1. Planning to undergo a radical prostatectomy (RALP) or laser enucleation of the prostate (LEP) procedure\n2. Patient of URMC Urology\n3. Adult male 18 years of age and older\n4. Able to read, write, and speak in English (NOTE: due to limitations with questionnaire validation, only English-speaking subjects are permitted)\n5. Has access to a mobile device capable of receiving automated text messages.\n6. Willing to receive text messages and to complete questionnaires via SMS text.\n7. Willingness to participate and able to provide informed consent.\n\nExclusion Criteria:\n\n1. Less than 18 years of age\n2. Unable to send and receive SMS texts\n3. Unable to read, write, and speak English\n4. Catheter dependency\n5. Has or plans to have Artificial Urinary Sphincter or Urethral Sling during the study period\n6. In the opinion of the investigator, the subject has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate.",{"count":65,"type":21},132,[24],"The purpose of this study is to compare post-prostatectomy incontinence via Michigan Incontinence Score Index in patients receiving daily text message reminders for pelvic floor exercises when compared to those not receiving text reminders.",[69,70,29],"Incontinence, Urinary Stress","Prostate Cancer","2025-11-04",{"date":73,"type":47},"2025-11-06",{"date":75,"type":47},"2025-09-15",{"date":77,"type":21},"2028-05-01",{"name":79,"class":54},"University of Rochester",1,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":88,"targetDuration":90,"studyType":91,"phases":4,"briefSummary":92,"conditions":93,"keywords":96,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":4},"100345308","registry-tpla-for-luts-100345308","NCT03776006","Registry: TPLA for LUTS","Registry of Transperineal Laser Ablation for Treatment of Lower Urinary Tract Symptoms With Use of the Echolaser® Device: A Multicentre, International Registry to Evaluate the Treatment of LUTS in Terms of Long-term Efficacy, Functional Outcomes and Safety","Inclusion Criteria:\n\n* Male\n* Presenting with lower urinary tract symptoms\n* Indication for transperineal laser ablation\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Previous or active treatment for prostate cancer (active surveillance is not seen as active treatment)",{"count":89,"type":21},500,"5 Years","OBSERVATIONAL","Rationale: The treatment of lower urinary tract symptoms (LUTS) due to benign prostatic enlargement in men with transperineal laser ablation (TPLA) may offer advantages in functional outcomes and safety over current standard therapies. As the technique is relatively new, indications and outcomes for this treatment are subject of investigation. However, the technique is already applied outside clinical studies. Clinical information from these treatments can be useful for future research. The aim of this study is to collect data on patients treated with transperineal laser ablation of the prostate outside clinical trials and to provide data on safety and functional outcomes in these patients in order to improve treatment.\n\nObjective: To assess long-term efficacy of transperineal laser ablation for lower urinary tract symptoms, to assess functional outcomes, to assess safety, to determine baseline patient characteristics, to collect information on possible differences between centres applying treatment of transperineal laser ablation and to explore the optimal treatment indications and possible limitations.\n\nStudy design: This is an international prospective observational study in which data is recorded of patients who are treated with transperineal laser ablation for lower urinary tract symptoms.\n\nStudy population: Male patients treated with transperineal laser ablation for lower urinary tract symptoms due to benign prostatic enlargement.\n\nMain study parameters\u002Fendpoints: The primary endpoint of this study is long-term efficacy of transperineal laser ablation for lower urinary tract symptoms measured by the time until surgical retreatment.",[94,29,95],"Lower Urinary Tract Symptoms","Benign Prostatic Hypertrophy With Outflow Obstruction",[97,98],"Transperineal laser ablation","LUTS","NOT_YET_RECRUITING","2019-01-17",{"date":102,"type":47},"2019-01-18",{"date":104,"type":21},"2019-02-01",{"date":106,"type":21},"2029-02-01",{"name":108,"class":54},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)"]